KIAA1549-BRAF fusions and IDH mutations can coexist in diffuse gliomas of adults

Brain Pathology

Volumn 22, Issue 6, 2012, Pages 841-847

  Badiali, Manuela ^a   Gleize, Vincent ^b   Paris, Sophie ^b   Moi, Loredana ^a   Elhouadani, Selma ^b   Arcella, Antonietta ^c   Morace, Roberta ^c   Antonelli, Manila ^d   Buttarelli, Francesca Romana ^d   Figarella Branger, Dominique ^e   Kim, Young Ho ^f   Ohgaki, Hiroko ^f   Mokhtari, Karima ^b   Sanson, Marc ^b   Giangaspero, Felice ^c  

^a Osp Regionale per le Microcitemie   (Italy)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c IRCCS NEUROMED   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e TIMONE HOSPITAL   (France)

^f INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

Author keywords

1p19q loss; BRAF mutation; deregulation of the Ras RAF ERK signaling pathway; diffuse gliomas; IDH1 mutation; KIAA1549 BRAF fusion gene

Indexed keywords

B RAF KINASE; ISOCITRATE DEHYDROGENASE; MITOGEN ACTIVATED PROTEIN KINASE; RAS PROTEIN;

ADULT; AGED; ARTICLE; ASTROCYTOMA; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME DELETION; CHROMOSOME LOSS; FEMALE; FUSION GENE; GENE MUTATION; GENE SEQUENCE; GENETIC SCREENING; GLIOBLASTOMA; GLIOMA; HUMAN; HUMAN TISSUE; KIAA1549 BRAF GENE; MAJOR CLINICAL STUDY; MALE; OLIGODENDROGLIOMA; PILOCYTIC ASTROCYTOMA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

ADULT; AGED; AGED, 80 AND OVER; BRAIN NEOPLASMS; FEMALE; GLIOMA; HUMANS; ISOCITRATE DEHYDROGENASE; MALE; MIDDLE AGED; ONCOGENE PROTEINS, FUSION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; YOUNG ADULT;

EID: 84867574186     PISSN: 10156305     EISSN: 17503639     Source Type: Journal    
DOI: 10.1111/j.1750-3639.2012.00603.x     Document Type: Article

References (23)

1. Antonelli M, Buttarelli FR, Arcella A, Nobusawa S, Donofrio V, Oghaki H, Giangaspero F, (2010) Prognostic significance of histological grading, p53 status, YKL-40 expression, and IDH1 mutations in pediatric high-grade gliomas. J Neurooncol 2: 209-215.
2. Bar EE, Lin A, Tihan T, Burger PC, Eberhart CG, (2008) Frequent gains at chromosome 7q34 involving BRAF in pilocytic astrocytoma. J Neuropathol Exp Neurol 9: 878-887.
3. Bettegowda C, Agrawal N, Jiao Y, Sausen M, Wood LD, Hruban RH, et al, (2011) Mutations in CIC and FUBP1 contribute to human oligodendroglioma. Science 333: 1453-1455.
4. Bissola L, Eoli M, Pollo B, Merciai BM, Silvani A, Salsano E, et al, (2002) Association of chromosome 10 losses and negative prognosis in oligoastrocytomas. Ann Neurol 52: 842-845.
5. Forshew T, Tatevossian RG, Lawson AR, Ma J, Neale G, Ogunkolade BW, et al, (2009) Activation of the ERK/MAPK pathway: a signature genetic defect in posterior fossa pilocytic astrocytomas. J Pathol 2: 172-181.
6. Hawkins C, Walker E, Mohamed N, Zhang C, Jacob K, Shirinian M, et al, (2011) BRAF-KIAA1549 fusion predicts better clinical outcome in pediatric low-grade astrocytoma. Clin Cancer Res 14: 4790-4798.
7. Horbinski C, Miller CR, Perry A, (2011) Gone FISHing: clinical lessons learned in brain tumor molecular diagnostics over the last decade. Brain Pathol 1: 57-73.
8. Idbaih A, Marie Y, Lucchesi C, Pierron G, Manié E, Raynal V, et al, (2008) BAC array CGH distinguishes mutually exclusive alterations that define clinicogenetic subtypes of gliomas. Int J Cancer 8: 1778-1786.
9. Jones DT, Kocialkowski S, Liu L, Pearson DM, Bäcklund LM, Ichimura K, Collins VP, (2008) Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res 21: 8673-8677.
10. Jones DT, Kocialkowski S, Liu L, Pearson DM, Ichimura K, Collins VP, (2009) Oncogenic RAF1 rearrangement and a novel BRAF mutation as alternatives to KIAA1549:BRAF fusion in activating the MAPK pathway in pilocytic astrocytoma. Oncogene 20: 2119-2123.
11. Korshunov A, Meyer J, Capper D, Christians A, Remke M, Witt H, et al, (2009) Combined molecular analysis of BRAF and IDH1distinguishes pilocytic astrocytoma from diffuse astrocytoma. Acta Neuropathol 3: 401-405.
12. Lin A, Rodriguez FJ, Karajannis MA, Williams SC, Legault G, Zagzag D, et al, (2012) BRAF alterations in primary glial and glioneuronal neoplasms of the central nervous system with identification of 2 novel KIAA1549: BRAF fusion variants. J Neuropathol Exp Neurol 1: 66-72.
13. Louis D, Ohgaki H, Wiestler OD, WK Cavanee editors (2007) WHO Classification of Tumors: Pathology and Genetics of Tumours of the Nervous System. IARC Press: Lyon.
14. Nobusawa S, Watanabe T, Kleihues P, Ohgaki H, (2009) IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res 15: 6002-6007.
15. Pfister S, Janzarik WG, Remke M, Ernst A, Werft W, Becker N, et al, (2008) BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. J Clin Invest 5: 1739-1749.
16. Pollack IF, Hamilton RL, Sobol RW, Nikiforova MN, Lyons-Weiler MA, LaFramboise WA, et al,; Children's Oncology Group (2011) IDH1 mutations are common in malignant gliomas arising in adolescents: a report from the Children's Oncology Group. Childs Nerv Syst 1: 87-94.
17. Schindler G, Capper D, Meyer J, Janzarik W, Omran H, Herold-Mende C, et al, (2011) Analysis of BRAF V600E mutation in 1.320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol 3: 397-405.
18. Sievert AJ, Jackson EM, Gai X, Hakonarson H, Judkins AR, Resnick AC, et al, (2009) Duplication of 7q34 in pediatric low-grade astrocytomas detected by high-density single-nucleotide polymorphism-based genotype arrays results in a novel BRAF fusion gene. Brain Pathol 3: 449-458.
19. Tatevossian RG, Lawson AR, Forshew T, Hindley GF, Ellison DW, Sheer D, (2010) MAPK pathway activation and the origins of pediatric low-grade astrocytomas. J Cell Physiol 3: 509-514.
20. Tian Y, Rich BE, Vena N, Craig JM, Macconaill LE, Rajaram V, et al, (2011) Detection of KIAA1549-BRAF fusion transcripts in formalin-fixed paraffin-embedded pediatric low-grade gliomas. J Mol Diagn 6: 669-677.
21. Watanabe T, Nobusawa S, Kleihues P, Ohgaki H, (2009) IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 4: 1149-1153.
22. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, et al, (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 8: 765-773.
23. Yip S, Butterfield YS, Morozova O, Chittaranjan S, Blough MD, An J, et al, (2012) Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers. J Pathol 1: 7-16.